Literature DB >> 25544714

Thyroid dysfunction after intra-arterial chemotherapy for hypopharyngeal and laryngeal cancer.

Kazuhira Endo1, Tomomi Masatani2, Akira Tsuji2, Satoru Kondo2, Naohiro Wakisaka2, Shigeyuki Murono2, Tomokazu Yoshizaki2.   

Abstract

OBJECTIVE: Hypothyroidism is a late side effect after curative radiotherapy in the head and neck region. Superselective intra-arterial chemotherapy (SSIAC), when combined with radiation (SSIAC-R), shows higher control potential for locally advanced head and neck cancers, which is attributable to a delivery of higher concentrations of chemotherapeutic agents. However, it could enhance damages in the normal tissues. Hypothyroidism is a late adverse effect after curative radiotherapy in the head and neck region. This study focuses on the toxic effect of treatment modality for thyroid function.
METHODS: A retrospective analysis was performed to examine patients' thyroid function after SSIAC-R for laryngeal and hypopharyngeal cancer.
RESULTS: Hypothyroidism was observed in 21 (77.8%) of 27 patients receiving SSIAC-R, 4 (33.3%) of 12 patients treated with radiation alone, and 7 (41.1%) of 17 who underwent systemic chemoradiotherapy. The number of administered vessels significantly correlated with the incidence of developing hypothyroidism among SSIAC-R treated patients (P=0.03).
CONCLUSION: Concurrent setting of SSIAC with radiation significantly raises the possibility of hypothyroidism. Therefore, monitoring late complications of therapeutic procedures is essential during follow-up visits.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Head and neck squamous cell carcinoma; Health-related quality of life; Hypothyroidism; Intra-arterial chemotherapy; Radiation

Mesh:

Substances:

Year:  2014        PMID: 25544714     DOI: 10.1016/j.anl.2014.12.002

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  2 in total

1.  Thyroid dysfunction during PD-1 inhibitor treatment in patients with cancer: Incidence and association with progression-free survival.

Authors:  Yanfei Wu; Zhi Wang; Hongxia Bai; Yan Gao
Journal:  Oncol Lett       Date:  2022-07-13       Impact factor: 3.111

2.  Targeting PD-L1 (Programmed death-ligand 1) and inhibiting the expression of IGF2BP2 (Insulin-like growth factor 2 mRNA-binding protein 2) affect the proliferation and apoptosis of hypopharyngeal carcinoma cells.

Authors:  Xudong Yang; Jisheng Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.